Altered expression of beta 1 integrins in renal carcinoma cell lines exposed to vinblastine.
BACKGROUND
Cellular expression of P-glycoprotein (P-gp) which mediates a well characterized mechanism of multidrug resistance (MDR) has been reported previously to be associated with an enhanced tumor dissemination. Since adhesion receptors of the beta 1 integrin family play a substantial role in tumor spread, we studied expression of VLA-1 to -6 in a total of four renal carcinoma cell (RCC) lines prior to and after induction of MDR via exposure to vinblastine.


METHODS
Surface expression of P-gp and VLA-1 to -6 was determined immunocytochemically in untreated pre-established renal carcinoma cell lines (Caki-1, Caki-2, A498) and a cell line derived from a RCC patient who had received a vinblastine-containing therapy regimen prior to the resection of a local relapse of the tumor (EH). Resistant sublines were cultivated in the presence of 1 ng/ml and 10 ng/ml of vinblastine sulfate, respectively.


RESULTS
In all cell lines examined, an increased number of P-gp expressing cells was observed upon exposure to vinblastine. Significant changes of beta 1 integrin expression were observed in three of four RCC cell lines. A de novo expression of VLA-1, VLA-2, and VLA-4 as detected by immunocytochemistry occurred in resistant Caki-1 cells. A498 cells showed an increasing number of VLA-2 positive cells in drug resistant sublines. In contrast, a decrease of VLA-2 and VLA-5 expression was found in EH cells, the only cell line exhibiting P-gp expression prior to vinblastine exposure. Caki-2 cells showed no significant changes of surface integrin expression upon treatment with vinblastine.


CONCLUSIONS
Our results demonstrate that induction of drug resistance can be associated with substantial changes of the integrin phenotype in renal carcinoma cell lines. In our experiments, among all VLAs studied, VLA-2 was most frequently altered in expression by RCC cell lines. The significance of these observations for aberrant metastatic properties of multidrug resistant tumor cells will be the subject of further studies.
Meyer
N
N
Department of Hematology and Oncology, Medizinische Hochschule Hannover, Germany.
Duensing
S
S
Anastassiou
G
G
Brevis Nunez
F
F
Grosse
J
J
Ganser
A
A
Atzpodien
J
J
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000276:immunology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D039222:Integrin alpha1beta1; D039201:Integrin alpha3beta1; D039041:Integrin alpha4beta1; D039121:Integrin alpha6beta1; D019012:Integrin beta1 / Q000096:biosynthesis / Q000235:genetics*; D016023:Integrins / Q000235:genetics; D007680:Kidney Neoplasms / Q000276:immunology*; D009364:Neoplasm Recurrence, Local; D038981:Receptors, Collagen; D017469:Receptors, Fibronectin / Q000235:genetics; D016201:Receptors, Lymphocyte Homing / Q000235:genetics; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000633:toxicity*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D039222:Integrin alpha1beta1; D039201:Integrin alpha3beta1; D039041:Integrin alpha4beta1; D039121:Integrin alpha6beta1; D019012:Integrin beta1; D016023:Integrins; D038981:Receptors, Collagen; D017469:Receptors, Fibronectin; D016201:Receptors, Lymphocyte Homing; D014747:Vinblastine